8:18 AM Endologix (ELGX) reports preliminary unaudited sales for Q2 of ~$34M (+33% Y/Y) and raises FY13 revenue guidance to $128-134M. The company now projects a wider net loss than previously expected however and also says it is temporarily suspending enrollment in its Ventana U.S. IDE clinical trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.